Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMIKACIN SULFATE vs ACULAR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting protein synthesis. Also disrupts bacterial cell membrane integrity.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever.
FDA-approved: Treatment of serious gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Escherichia coli, Klebsiella, Enterobacter, Serratia, Proteus) when other antibiotics are ineffective or contraindicated.,Off-label: Used in combination for enterococcal endocarditis, mycobacterial infections (e.g., tuberculosis), and severe neonatal sepsis.
Treatment of postoperative inflammation in patients who have undergone cataract extraction,Relief of ocular itching due to seasonal allergic conjunctivitis
15 mg/kg/day IV or IM divided every 8-12 hours; typical adult dose 500 mg IV/IM every 12 hours or 7.5 mg/kg every 12 hours.
One drop of 0.5% ophthalmic solution into the affected eye(s) four times daily.
Terminal: 2-3 hours (normal renal function); prolonged to 30-50 hours in anuria; neonates 4-8 hours.
Terminal half-life: 1.8 hours (ketorolac tromethamine); clinical context: short half-life supports dosing every 6 hours for acute pain, but prolonged in elderly or renal impairment (↑ to 5-6 hours, thus dose reduction required).
Amikacin is not significantly metabolized; it is excreted unchanged primarily by glomerular filtration. Minimal hepatic metabolism.
Hepatic metabolism primarily via cytochrome P450 2C9 (CYP2C9).
Renal: >90% unchanged via glomerular filtration. Biliary/fecal: <1%.
Renal: ~80% as unchanged drug and glucuronide conjugates; biliary/fecal: ~20%
0-11% (low binding to albumin).
99% bound; primary binding protein: albumin.
0.25-0.4 L/kg; approximates extracellular fluid volume; increased in edema, decreased in dehydration.
0.11-0.25 L/kg; clinical meaning: low Vd indicates primarily confined to extracellular compartment (plasma and interstitial fluid), minimal tissue penetration.
IM: nearly 100% (rapid and complete).
Ophthalmic: ~2% systemic absorption after topical instillation (due to corneal permeability and nasolacrimal drainage); oral formulation not used for Acular (ophthalmic only).
Cr Cl 20-50 m L/min: 7.5 mg/kg every 24 hours; Cr Cl 10-20 m L/min: 7.5 mg/kg every 48 hours; Cr Cl <10 m L/min: 7.5 mg/kg every 72-96 hours; hemodialysis: 7.5 mg/kg post-dialysis with monitoring.
No dosage adjustment required for renal impairment.
No dose adjustment required for hepatic impairment; monitor drug levels if severe dysfunction.
No dosage adjustment required for hepatic impairment.
Neonates <7 days: 15-20 mg/kg IV every 24-48 hours; neonates 7-28 days: 15 mg/kg every 24 hours; infants/children: 15-22.5 mg/kg/day divided every 8-12 hours; maximum 1.5 g/day.
Safety and efficacy in pediatric patients have not been established; use not recommended.
Reduce initial dose based on renal function; usual dose 7.5 mg/kg every 24-48 hours with close monitoring of serum creatinine and drug levels due to age-related decreased GFR.
No specific dosage adjustment required; use same dosing as for younger adults.
WARNING: Amikacin can cause neurotoxicity, ototoxicity, and nephrotoxicity. The risk of nephrotoxicity is greater in patients with impaired renal function and those receiving high doses or prolonged therapy. Ototoxicity may be irreversible and can occur even after drug discontinuation. Monitor renal function and drug levels closely.
No FDA boxed warning.
Nephrotoxicity: Risk increased with advanced age, pre-existing renal impairment, concomitant use of other nephrotoxic drugs (e.g., amphotericin B, cyclosporine, NSAIDs).,Ototoxicity: Can cause irreversible bilateral hearing loss, tinnitus, and vestibular damage. Monitor audiometry in patients with risk factors.,Neuromuscular blockade: May exacerbate weakness in patients with neuromuscular disorders (e.g., myasthenia gravis, Parkinsonism). Use with caution during anesthesia or with neuromuscular blocking agents.,Hypersensitivity reactions: Including rash, drug fever, and anaphylaxis.,Superinfection: Prolonged use may lead to overgrowth of nonsusceptible organisms.,Pregnancy: Risk of fetal harm (ototoxicity) if administered during pregnancy.
May increase bleeding time due to inhibition of platelet aggregation; use with caution in patients with known bleeding tendencies or those receiving other medications that may prolong bleeding time.,May cause corneal effects including keratitis and corneal thinning; discontinue if corneal epithelial breakdown occurs.,Use with caution in patients with prior sensitivity to aspirin, phenylacetic acid derivatives, or other NSAIDs.,May delay wound healing or exacerbate infections; avoid use in patients with active epithelial herpes simplex keratitis.
Hypersensitivity to amikacin, other aminoglycosides, or any component of the formulation.,Preexisting severe renal impairment (unless life-threatening infection and no alternative).,Concurrent use of other nephrotoxic or ototoxic drugs (relative contraindication).,Myasthenia gravis (caution; neuromuscular blocking effect).
Hypersensitivity to ketorolac tromethamine or any component of the formulation,History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs,Active epithelial herpes simplex keratitis,Late pregnancy (third trimester) due to risk of premature closure of ductus arteriosus
No significant food interactions. Avoid alcohol as it may increase side effects like dizziness.
No known food interactions. Avoid alcohol if concomitant oral NSAIDs are used due to increased risk of gastrointestinal bleeding, but this is not specific to ophthalmic use.
Aminoglycosides including amikacin have been associated with fetal ototoxicity and nephrotoxicity when administered during pregnancy. There is a potential for eighth cranial nerve damage and renal impairment in the fetus, particularly during the second and third trimesters. Animal studies have shown evidence of harm, but controlled human studies are lacking. Use only if clearly needed and if safer alternatives are unavailable.
Pregnancy Category C. No adequate studies in pregnant women. Ketorolac tromethamine, like other NSAIDs, may cause premature closure of the ductus arteriosus and fetal renal impairment in the third trimester. First and second trimester use should be avoided unless clearly needed. The potential benefits should be weighed against the risks.
Amikacin is excreted into human milk in low concentrations. The milk-to-plasma ratio is approximately 0.1–0.2. Due to low oral bioavailability from the gastrointestinal tract, systemic effects in the breastfed infant are unlikely. However, caution is advised due to the potential for altered infant gut flora and direct mucosal irritation. Use only if benefits outweigh risks.
Ketorolac is excreted in human milk at low levels. The M/P ratio is not well defined. Due to potential adverse effects in nursing infants, caution is advised. Use only if clearly indicated and consider alternative agents.
Pregnancy does not typically require dosing adjustments for amikacin. However, due to increased glomerular filtration rate during pregnancy, levels may be lower; monitor drug concentrations and adjust doses to achieve therapeutic range. Standard dosing based on ideal body weight and renal function should be followed.
No specific dose adjustments are recommended for pregnancy; however, use the lowest effective dose for the shortest duration due to potential fetal risks. Physiological changes in pregnancy (increased volume of distribution, renal clearance) may alter pharmacokinetics, but no formal studies justify dose modification.
Monitor peak (15-30 mcg/m L) and trough (<5 mcg/m L) levels to avoid nephrotoxicity and ototoxicity. Adjust dose in renal impairment using Cr Cl. Synergy with beta-lactams for Gram-negative infections. Avoid concurrent loop diuretics.
ACULAR (ketorolac tromethamine ophthalmic solution) is a nonsteroidal anti-inflammatory drug (NSAID) used for ocular inflammation. Avoid concomitant use with other NSAIDs or corticosteroids due to increased risk of corneal adverse events. Use with caution in patients with bleeding disorders or those on anticoagulants, as it may increase bleeding tendency. Monitor for corneal toxicity, especially in patients with compromised corneal integrity. Ensure proper storage at room temperature and discard if solution changes color or becomes cloudy.
Take exactly as prescribed; do not skip doses or stop early.,Report any hearing loss, tinnitus, dizziness, or vertigo immediately.,Drink plenty of fluids to maintain hydration, unless contraindicated.,Avoid taking other medications without consulting your doctor, especially water pills or other antibiotics.
Do not touch the dropper tip to any surface to avoid contamination.,Remove contact lenses before instillation and wait at least 15 minutes before reinserting.,Apply pressure to the inner corner of the eye (nasolacrimal occlusion) for 1 minute after instillation to reduce systemic absorption.,Do not use while wearing soft contact lenses, as the preservative may be absorbed.,Report any signs of corneal problems such as pain, redness, or vision changes immediately.,Use exactly as prescribed and do not share the medication with others.
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the renal tubular secretion and potentially reduce the clearance of masoprocol, a dicarboxylic acid derivative used as a chemotherapeutic agent. This interaction could lead to increased systemic exposure to masoprocol, elevating the risk of dose-dependent toxicities such as severe enteritis, myelosuppression, and hepatotoxicity. Given the narrow therapeutic index of masoprocol, even modest elevations in serum levels may result in clinically significant adverse outcomes."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the tubular secretion of mycophenolic acid (MPA) in the renal proximal tubules, leading to reduced renal clearance of MPA. This interaction can result in elevated serum levels of MPA, increasing the risk of dose-related toxicities such as bone marrow suppression (leukopenia, thrombocytopenia), gastrointestinal disturbances, and increased susceptibility to infections. Patients receiving this combination should be closely monitored for signs of MPA toxicity, especially those with pre-existing renal impairment."
"Coadministration of Metocurine, a nondepolarizing neuromuscular blocking agent, with Amikacin, an aminoglycoside antibiotic, may result in enhanced and prolonged neuromuscular blockade. Aminoglycosides can impair acetylcholine release from presynaptic nerve terminals and reduce postsynaptic sensitivity, synergistically augmenting the effects of nondepolarizing agents. This interaction can lead to excessive muscle relaxation, including respiratory muscle paralysis, increasing the risk of apnea and postoperative respiratory depression."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMIKACIN SULFATE vs ACULAR, answered by our medical review team.
AMIKACIN SULFATE is a Aminoglycoside Antibiotic that works by Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting protein synthesis. Also disrupts bacterial cell membrane integrity.. ACULAR is a NSAID Ophthalmic that works by Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMIKACIN SULFATE and ACULAR depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMIKACIN SULFATE is: 15 mg/kg/day IV or IM divided every 8-12 hours; typical adult dose 500 mg IV/IM every 12 hours or 7.5 mg/kg every 12 hours.. The standard adult dose of ACULAR is: One drop of 0.5% ophthalmic solution into the affected eye(s) four times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMIKACIN SULFATE and ACULAR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMIKACIN SULFATE is classified as Category D/X. Aminoglycosides including amikacin have been associated with fetal ototoxicity and nephrotoxicity when administered during pregnancy. There is a potential for eighth cranial nerve . ACULAR is classified as Category C. Pregnancy Category C. No adequate studies in pregnant women. Ketorolac tromethamine, like other NSAIDs, may cause premature closure of the ductus arteriosus and fetal renal impairm. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.